top of page
Search

New Hope for Treatment-Resistant Depression: GH001 Shows Remarkable Results in Phase 2b Trial

If you've been following the psychedelic therapy space, you know the promise has always been tantalizing but the clinical evidence has taken time to catch up. That's changing. GH Research just released results from their Phase 2b trial of GH001—an inhalable form of 5-MeO-DMT—and the numbers are nothing short of remarkable.

The Problem: Treatment-Resistant Depression

Depression affects hundreds of millions worldwide. But for a significant subset—those with treatment-resistant depression (TRD)—traditional antidepressants, therapy, and even newer interventions don't work. These are people who've tried medication after medication, often for years, without meaningful relief.

"Most TRD patients have not benefited from a number of established treatment options and this illness frequently imposes years of insurmountable mental suffering and disabling effects on social and vocational functioning." — Dr. Michael E. Thase, University of Pennsylvania

What GH001 Actually Is

GH001 is a proprietary inhalable formulation of 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine)—a naturally occurring psychedelic found in certain plants and the venom of the Sonoran Desert toad. Unlike longer-acting psychedelics like psilocybin or LSD, 5-MeO-DMT produces a short but profound experience, typically lasting 15-45 minutes.

The innovation from GH Research isn't the molecule itself—it's the delivery method. Inhalation allows for precise dosing and rapid onset, which is critical for clinical settings.

Neuroscience and brain research concept

The Trial Results: By the Numbers

The Phase 2b trial enrolled 81 participants with treatment-resistant depression: 40 patients received GH001 and 41 patients received placebo.

Primary Outcome: Rapid Effect

At Day 8, patients who received GH001 showed a 15.2-point improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS)—a standard measure of depression severity. The placebo-adjusted difference was 15.5 points.

To put that in context: a 3-point change on MADRS is considered clinically meaningful. This trial showed a change more than five times that threshold.

Remission Rates: The Real Story

Here's where it gets extraordinary:

  • 57.7% of GH001 patients achieved remission (MADRS ≤10) vs. 0% in the placebo group

  • At 6 months, 77.8% of patients who completed the study remained in remission

  • Most patients (60.3%) needed only 1-4 treatments over the entire 6-month period

Read that again: patients who hadn't responded to anything else achieved remission—and maintained it—with just a handful of short clinic visits.

Safety Profile

The trial found GH001 was well-tolerated:

  • Only mild or moderate adverse events during the double-blind phase

  • Stable vital signs (heart rate, blood pressure, ECG)

  • No sedation or dissociative symptoms at discharge

  • 97.4% of patients were discharge-ready within an hour of their last dose

This is significant. One of the barriers to psychedelic therapy adoption has been concerns about safety and the logistical burden of long supervision periods. A treatment that allows discharge within an hour changes the calculus entirely.

What This Means for the Future

Dr. Thase called the results "truly remarkable" and noted that "a novel treatment with such a large and rapid effect, particularly one that may require only infrequent, short 1-3 hour clinic visits, has the potential to be a practice changing treatment."

If these results hold through Phase 3 trials and regulatory approval, we're looking at:

  1. A new option for people who've lost hope — For TRD patients, this could be the first thing that actually works

  2. A practical clinical model — Short visits, infrequent dosing, rapid discharge

  3. Validation of psychedelic approaches — More evidence that these molecules deserve serious scientific attention

The Bigger Picture

This trial is part of a larger shift in psychiatry. We're moving away from the "take this pill every day forever" model toward targeted interventions that address root causes. Psychedelics—when administered properly in clinical settings—appear to do something fundamentally different than traditional antidepressants.

They don't just mask symptoms. They seem to create windows of neuroplasticity where lasting change becomes possible.

Of course, this research is still in clinical trials. GH001 isn't available yet, and anyone seeking 5-MeO-DMT treatment should do so only with trained facilitators who understand the profound nature of this experience.

But for those of us who've witnessed the transformative potential of these medicines firsthand, this trial is validation. The data is catching up to what we've seen. And that's very, very good news.

Sources

  • GH Research Press Release, February 3, 2025

  • Puigseslloses P, et al. "Structure-activity relationships of serotonergic 5-MeO-DMT derivatives." Mol Psychiatry. 2024;29:2346-2358.

Comments

bottom of page